Biosplice Therapeutics

Biosplice Therapeutics is developing first-in-class small molecule therapies based on groundbreaking science in alternative pre-mRNA splicing. Stemming from fundamental discoveries in Wnt pathway modulation, Biosplice has uncovered novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is a critical biological mechanism that regulates protein diversity within cells, which in turn determines cell type and function. Biosplice's target class controls the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cell’s "command and control" center.Biosplice’s clinical-stage pipeline includes lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for various cancers, and a broad portfolio ranging from Alzheimer’s disease to other degenerative conditions.